{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T09:34:27Z","timestamp":1774863267966,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T00:00:00Z","timestamp":1600214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T00:00:00Z","timestamp":1600214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["NMRC\/STaR\/0022\/2014"],"award-info":[{"award-number":["NMRC\/STaR\/0022\/2014"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["NMRC\/CSA-SI\/0011\/2017"],"award-info":[{"award-number":["NMRC\/CSA-SI\/0011\/2017"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["NMRC\/CSA\/028\/2011"],"award-info":[{"award-number":["NMRC\/CSA\/028\/2011"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["CS\/14\/3\/31002"],"award-info":[{"award-number":["CS\/14\/3\/31002"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000921","name":"European Cooperation in Science and Technology","doi-asserted-by":"publisher","award":["EU-CARDIOPROTECTION CA16225"],"award-info":[{"award-number":["EU-CARDIOPROTECTION CA16225"]}],"id":[{"id":"10.13039\/501100000921","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Pivotal trials of beta-blockers (BB) and angiotensin converting enzyme inhibitors\/angiotensin receptor blockers (ACEI\/ARB) in acute myocardial infarction (AMI) were largely conducted prior to the widespread adoption of early revascularization. A total of 15,073 patients with AMI who underwent inhospital coronary revascularization from January 2007 to December 2013 were analyzed. At 12\u00a0months, BB was significantly associated with a lower incidence of major adverse cardiovascular events (MACE, adjusted HR 0.80, 95% CI 0.70\u20130.93) and all-cause mortality (adjusted HR 0.69, 95% CI 0.55\u20130.88), while ACEI\/ARB was significantly associated with lower all-cause mortality (adjusted HR 0.80, 95% CI 0.66\u20130.98) and heart failure (HF) hospitalization (adjusted HR 0.80, 95% CI 0.68\u20130.95). Combined BB and ACEI\/ARB use was associated with the lowest incidence of MACE (adjusted HR 0.70, 95% CI 0.57\u20130.86), all-cause mortality (adjusted HR 0.55, 95% CI 0.40\u20130.77) and HF hospitalization (adjusted HR 0.64, 95% CI 0.48\u20130.86). This were consistent for left ventricular ejection fraction &lt;\u200950% or \u2265\u200950%. In conclusion, in AMI managed with revascularization, both BB and ACEI\/ARB were associated with a lower incidence of 12-month all-cause mortality. Combined BB and ACEI\/ARB was associated with the lowest incidence of all-cause mortality and HF hospitalization.<\/jats:p>","DOI":"10.1038\/s41598-020-72232-y","type":"journal-article","created":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T10:03:22Z","timestamp":1600250602000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Beta-blockers and renin-angiotensin system inhibitors in acute myocardial infarction managed with inhospital coronary revascularization"],"prefix":"10.1038","volume":"10","author":[{"given":"Hui Wen","family":"Sim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huili","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. Mark","family":"Richards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth W.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Sahlen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khung-Keong","family":"Yeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack W.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terrance","family":"Chua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huay Cheem","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiong Cheng","family":"Yeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hee Hwa","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boon-Wah","family":"Liew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling Li","family":"Foo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Hang","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derek J.","family":"Hausenloy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark Y.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,16]]},"reference":[{"key":"72232_CR1","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1136\/bmj.318.7200.1730","volume":"318","author":"N Freemantle","year":"1999","unstructured":"Freemantle, N. et al. Beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 318, 1730\u20131737 (1999).","journal-title":"BMJ"},{"key":"72232_CR2","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1056\/NEJM199808203390801","volume":"339","author":"S Stephen","year":"1998","unstructured":"Stephen, S. et al. Effect of beta-blockade on mortality among high-risk. N. Engl. J. Med. 339, 489\u2013497 (1998).","journal-title":"N. Engl. J. Med."},{"key":"72232_CR3","first-page":"821","volume":"342","author":"The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators","year":"1993","unstructured":"The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril myocardial infarction with clinical evidence of heart failure. Lancet 342, 821\u2013828 (1993).","journal-title":"Lancet"},{"key":"72232_CR4","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/S0140-6736(00)02212-1","volume":"355","author":"MD Flather","year":"2000","unstructured":"Flather, M. D. et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 355, 1575\u20131581 (2000).","journal-title":"Lancet"},{"key":"72232_CR5","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1056\/NEJMoa032292","volume":"349","author":"MA Pfeffer","year":"2003","unstructured":"Pfeffer, M. A. et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N. Engl. J. Med. 349, 1893\u20131906 (2003).","journal-title":"N. Engl. J. Med."},{"key":"72232_CR6","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/S0140-6736(02)09895-1","volume":"360","author":"K Dickstein","year":"2002","unstructured":"Dickstein, K. & Kjekshus, J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 360, 752\u2013760 (2002).","journal-title":"Lancet"},{"key":"72232_CR7","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/S0140-6736(03)14286-9","volume":"362","author":"T European","year":"2003","unstructured":"European, T. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study. Lancet 362, 782\u2013788 (2003).","journal-title":"Lancet"},{"key":"72232_CR8","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1016\/j.jacc.2017.03.578","volume":"69","author":"TB Dondo","year":"2017","unstructured":"Dondo, T. B. et al. \u03b2-blockers and mortality after acute myocardial infarction in patients without heart failure or ventricular dysfunction. J. Am. Coll. Cardiol. 69, 2710\u20132720 (2017).","journal-title":"J. Am. Coll. Cardiol."},{"key":"72232_CR9","doi-asserted-by":"publisher","first-page":"i4801","DOI":"10.1136\/bmj.i4801","volume":"354","author":"E Puymirat","year":"2016","unstructured":"Puymirat, E. et al. \u03b2 blockers and mortality after myocardial infarction in patients without heart failure: Multicentre prospective cohort study. BMJ 354, i4801 (2016).","journal-title":"BMJ"},{"key":"72232_CR10","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1016\/j.jacc.2015.07.047","volume":"66","author":"JJ Goldberger","year":"2015","unstructured":"Goldberger, J. J. et al. Effect of beta-blocker dose on survival after acute myocardial infarction. J. Am. Coll. Cardiol. 66, 1431\u20131441 (2015).","journal-title":"J. Am. Coll. Cardiol."},{"key":"72232_CR11","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1001\/jama.2012.12559","volume":"308","author":"K Crowley","year":"2012","unstructured":"Crowley, K. et al. Beta-blocker use and clinical outcomes. JAMA 308, 1340\u20131349 (2012).","journal-title":"JAMA"},{"key":"72232_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1161\/CIRCOUTCOMES.117.004356","volume":"11","author":"A Neumann","year":"2018","unstructured":"Neumann, A., Maura, G., Weill, A., Alla, F. & Danchin, N. Clinical events after discontinuation of \u03b2-blockers in patients without heart failure optimally treated after acute myocardial infarction. Circ. Cardiovasc. Qual. Outcomes 11, 1\u201314 (2018).","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"72232_CR13","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.amjmed.2014.05.032","volume":"127","author":"S Bangalore","year":"2014","unstructured":"Bangalore, S. et al. Clinical outcomes with \u03b2-blockers for myocardial infarction: A meta-analysis of randomized trials. Am. J. Med. 127, 939\u2013953 (2014).","journal-title":"Am. J. Med."},{"key":"72232_CR14","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"B Ibanez","year":"2018","unstructured":"Ibanez, B. et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur. Heart J. 39, 119\u2013177 (2018).","journal-title":"Eur. Heart J."},{"key":"72232_CR15","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1161\/CIR.0000000000000133","volume":"130","author":"EA Amsterdam","year":"2014","unstructured":"Amsterdam, E. A. et al. 2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary. Circulation 130, 2354\u20132394 (2014).","journal-title":"Circulation"},{"key":"72232_CR16","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1161\/CIR.0b013e3182742c84","volume":"127","author":"PT O\u2019Gara","year":"2012","unstructured":"O\u2019Gara, P. T. et al. 2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: executive summary. Circulation 127, 529\u2013555 (2012).","journal-title":"Circulation"},{"key":"72232_CR17","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1161\/CIRCRESAHA.114.302589","volume":"114","author":"VG Florea","year":"2014","unstructured":"Florea, V. G. et al. The autonomic nervous system and heart failure. Circ. Res. 114, 1815\u20131826 (2014).","journal-title":"Circ. Res."},{"key":"72232_CR18","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1161\/CIRCRESAHA.113.300308","volume":"113","author":"A Lymperopoulos","year":"2013","unstructured":"Lymperopoulos, A. et al. Adrenergic nervous system in heart failure: pathophysiology and therapy. Circ. Res. 113, 739\u2013753 (2013).","journal-title":"Circ. Res."},{"key":"72232_CR19","doi-asserted-by":"publisher","first-page":"2936","DOI":"10.1093\/eurheartj\/ehu131","volume":"35","author":"M Wolbers","year":"2014","unstructured":"Wolbers, M. et al. Competing risks analyses: objectives and approaches. Eur. Heart J. 35, 2936\u20132941 (2014).","journal-title":"Eur. Heart J."},{"key":"72232_CR20","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1253\/circj.CJ-10-1241","volume":"75","author":"M Konishi","year":"2011","unstructured":"Konishi, M. et al. Additive effects of \u03b2-blockers on renin-angiotensin system inhibitors for patients after acute myocardial infarction treated with primary coronary revascularization. Circ. J. 75, 1982\u20131991 (2011).","journal-title":"Circ. J."},{"key":"72232_CR21","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/S0140-6736(00)04560-8","volume":"357","author":"T.C. Investigators","year":"2001","unstructured":"T.C. Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 357, 1385\u20131390 (2001).","journal-title":"Lancet"},{"key":"72232_CR22","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1016\/j.amjcard.2015.02.057","volume":"115","author":"BT Huang","year":"2015","unstructured":"Huang, B. T. et al. Meta-analysis of relation between oral \u03b2-blocker therapy and outcomes in patients with acute myocardial infarction who underwent percutaneous coronary intervention. Am. J. Cardiol. 115, 1529\u20131538 (2015).","journal-title":"Am. J. Cardiol."},{"key":"72232_CR23","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.amjcard.2012.10.026","volume":"111","author":"D Nakatani","year":"2013","unstructured":"Nakatani, D. et al. Impact of beta blockade therapy on long-term mortality after ST-segment elevation acute myocardial infarction in the percutaneous coronary intervention era. Am. J. Cardiol. 111, 457\u2013464 (2013).","journal-title":"Am. J. Cardiol."},{"key":"72232_CR24","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1161\/CIRCOUTCOMES.114.001073","volume":"7","author":"S Bangalore","year":"2014","unstructured":"Bangalore, S. et al. \u03b2-blockers and cardiovascular events in patients with and without myocardial infarction: Post hoc analysis from the CHARISMA trial. Circ. Cardiovasc. Qual. Outcomes 7, 872\u2013881 (2014).","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"72232_CR25","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/S0735-1097(99)00634-8","volume":"35","author":"L Kj\u00f8ller-Hansen","year":"2000","unstructured":"Kj\u00f8ller-Hansen, L. et al. The angiotensin-converting enzyme inhibition post revascularization study (APRES). J. Am. Coll. Cardiol. 35, 881\u2013888 (2000).","journal-title":"J. Am. Coll. Cardiol."},{"key":"72232_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-019-00343-7","author":"M Cesp\u00f3n-Fern\u00e1ndez","year":"2019","unstructured":"Cesp\u00f3n-Fern\u00e1ndez, M. et al. Renin-angiotensin system blockade and risk of heart failure after myocardial infarction based on left ventricular ejection fraction: a retrospective cohort study. Am. J. Cardiovasc. Drugs https:\/\/doi.org\/10.1007\/s40256-019-00343-7 (2019).","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"72232_CR27","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1001\/archinte.166.6.659","volume":"166","author":"O Investigation","year":"2006","unstructured":"Investigation, O. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome. Arch. Intern. Med. 166, 659 (2006).","journal-title":"Arch. Intern. Med."},{"key":"72232_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/MD.0000000000004558","volume":"95","author":"PH Lee","year":"2016","unstructured":"Lee, P. H. et al. Effect of beta blockers and renin\u2014angiotensin system inhibitors on survival in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Medicine (Baltimore) 95, 1\u20137 (2016).","journal-title":"Medicine (Baltimore)"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-72232-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-72232-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-72232-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T19:29:52Z","timestamp":1670354992000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-72232-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,16]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["72232"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-72232-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,16]]},"assertion":[{"value":"16 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15184"}}